Journal
REVIEWS IN MEDICAL VIROLOGY
Volume 30, Issue 5, Pages -Publisher
WILEY
DOI: 10.1002/rmv.2136
Keywords
2019-nCoV; acetazolamide; acute respiratory distress syndrome (ARDS); autoimmune; camostat mesylate; chloroquine; COVID-19; high altitude pulmonary edema (HAPE); hydroxychloroquine; Lopinavir; Ritonavir; novel coronavirus 2019; pandemic; Remdesivir; RNA-dependent RNA polymerase inhibitors; SARS coronavirus (SARS-CoV); SARS CoV-2; severe acute respiratory syndrome (SARS); Umifenovir
Categories
Ask authors/readers for more resources
SARS-CoV-2 has caused a pandemic which is putting strain on the health-care system and global economy. There is much pressure to develop both preventative and curative therapies for SARS-CoV-2 as there is no evidence to support therapies to improve outcomes in patients with SARS-CoV-2. Medications that inhibit certain steps of virus life cycle that are currently used to treat other illnesses such as Malaria, Ebola, HIV and Hepatitis C are being studied for use against SARS-CoV-2. To date, data is limited for medications that facilitate clinical improvement of COVID-19 infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
